News & Press

‍

Thanks! You're subscribed.

Oops! Something went wrong while submitting the form.

February 2023

|

Press Release

Gradalis to Present at the 2023 BIO CEO & Investor Conference Gradalis to Present at the 2023 BIO CEO & Investor Conference

December 2022

|

Press Release

Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil® (gemogenovatucel-T) in Patients With Advanced Ovarian Cancer in the U.S.Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil® (gemogenovatucel-T) in Patients With Advanced Ovarian Cancer in the U.S.

December 2022

|

Press Release

Gradalis Appoints Eric Hall as Chief Financial Officer Gradalis Appoints Eric Hall as Chief Financial Officer

October 2022

|

Press Release

Gradalis to Present at the 2022 Cell & Gene Meeting on the Mesa Gradalis to Present at the 2022 Cell & Gene Meeting on the Mesa

October 2022

|

Press Release

Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors

September 2022

|

Press Release

Gradalis KOL Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®Gradalis KOL Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®

September 2022

|

Press Release

Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company's Immuno-Oncology Treatment, Vigil Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company's Immuno-Oncology Treatment, Vigil

September 2022

|

News Article

Gradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer Patients Gradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer Patients

August 2022

|

Press Release

Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®

June 2022

|

Press Release

Gradalis Appoints Steven Engle as Chief Executive Officer Gradalis Appoints Steven Engle as Chief Executive Officer

February 2022

|

Press Release

Gradalis and University of Michigan collaboration to utilize a patient's cancer cells to create personalized therapeutics to treat cancer Gradalis and University of Michigan collaboration to utilize a patient's cancer cells to create personalized therapeutics to treat cancer

March 2021

|

Press Release

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer

January 2021

|

Press Release

Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology

December 2020

|

News Article

Dr. Rod Rocconi on Med School Watercooler: Significant Results for Ovarian Cancer Patients Dr. Rod Rocconi on Med School Watercooler: Significant Results for Ovarian Cancer Patients

December 2020

|

News Article

Lancet Oncology: Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial Lancet Oncology: Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

June 2020

|

News Article

Gradalis at ASCO Virtual Scientific Forum - Randomized double-blind placebo-controlled trial of primary maintenance GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (VITAL study) in stage III/IV ovarian cancer Gradalis at ASCO Virtual Scientific Forum - Randomized double-blind placebo-controlled trial of primary maintenance GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (VITAL study) in stage III/IV ovarian cancer

April 2020

|

News Article

Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer

June 2019

|

News Article

Cancer Vaccine Developed In North Texas Could Be 'As Simple As A Flu Shot'Cancer Vaccine Developed In North Texas Could Be 'As Simple As A Flu Shot'

March 2019

|

Press Release

Gradalis Announces Medical Leadership Team Promotion Gradalis Announces Medical Leadership Team Promotion

November 2018

|

Press Release

Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group

October 2018

|

News Article

Gradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating their Phase 3 Study of Vigil™ in Ewing’s sarcoma Gradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating their Phase 3 Study of Vigil™ in Ewing’s sarcoma

August 2018

|

Press Release

Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma

See how we can help